The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors.
 
Caicun Zhou
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Yiping Zhang
No Relationships to Disclose
 
Zhengbo Song
No Relationships to Disclose
 
Yongsheng Wang
No Relationships to Disclose
 
Dingzhi Huang
No Relationships to Disclose
 
Feng Ye
No Relationships to Disclose
 
Qiming Wang
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma (Inst)
 
Yinghui Sun
Employment - Shouyao Holdings
Leadership - Shouyao Holdings
Stock and Other Ownership Interests - Shouyao Holdings
Honoraria - Shouyao Holdings
Patents, Royalties, Other Intellectual Property - Shouyao Holdings
Travel, Accommodations, Expenses - Shouyao Holdings